Solid Biosciences LLC (SLDB) — Cash Flow-to-Debt Ratio
Solid Biosciences LLC (SLDB) has a Cash Flow-to-Debt Ratio of -0.97x as of March 2026, meaning its operating cash flow of $-47.23 Million could theoretically repay -1% of its total liabilities ($48.76 Million) in one year. Check SLDB cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Solid Biosciences LLC Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Solid Biosciences LLC across 11 annual periods. Also explore Solid Biosciences LLC assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Solid Biosciences LLC (2015–2025)
Year-by-year debt coverage analysis for Solid Biosciences LLC. For market capitalisation and broader financial context, see Solid Biosciences LLC (SLDB) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.98x | $-156.29 Million | $52.53 Million | ▼ -53.0% |
| 2024 | -1.95x | $-100.01 Million | $51.42 Million | ▲ +20.6% |
| 2023 | -2.45x | $-94.18 Million | $38.46 Million | ▼ -21.4% |
| 2022 | -2.02x | $-97.98 Million | $48.59 Million | ▲ +37.3% |
| 2021 | -3.22x | $-77.76 Million | $24.17 Million | ▼ -122.2% |
| 2020 | -1.45x | $-56.60 Million | $39.08 Million | ▲ +63.4% |
| 2019 | -3.96x | $-92.71 Million | $23.42 Million | ▲ +18.7% |
| 2018 | -4.87x | $-70.20 Million | $14.41 Million | ▼ -1426.1% |
| 2017 | -0.32x | $-43.22 Million | $135.45 Million | ▼ -24.5% |
| 2016 | -0.26x | $-20.12 Million | $78.52 Million | ▼ -360.9% |
| 2015 | -0.06x | $-4.20 Million | $75.62 Million | — |